CLINICAL TRIALS PROFILE FOR ALITRETINOIN
✉ Email this page to a colleague
All Clinical Trials for Alitretinoin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00002188 ↗ | A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma | Completed | Ligand Pharmaceuticals | Phase 2 | 1969-12-31 | The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS). |
NCT00002188 ↗ | A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma | Completed | Anderson Clinical Research | Phase 2 | 1969-12-31 | The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS). |
NCT00002439 ↗ | A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma | Completed | Ligand Pharmaceuticals | N/A | 1969-12-31 | The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin . |
NCT00002439 ↗ | A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma | Completed | Anderson Clinical Research | N/A | 1969-12-31 | The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin . |
NCT00124436 ↗ | Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis | Completed | Basilea Pharmaceutica | Phase 3 | 2005-03-01 | Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to >75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment. |
NCT00124475 ↗ | Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis | Completed | Basilea Pharmaceutica | Phase 3 | 2004-12-01 | The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis. |
NCT00309621 ↗ | Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis | Completed | Basilea Pharmaceutica | Phase 3 | 2006-04-01 | Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Alitretinoin
Condition Name
Clinical Trial Locations for Alitretinoin
Trials by Country
Clinical Trial Progress for Alitretinoin
Clinical Trial Phase
Clinical Trial Sponsors for Alitretinoin
Sponsor Name